Regeneron Pharmaceuticals (REGN) Income from Non-Controlling Interests (2017 - 2019)
Regeneron Pharmaceuticals (REGN) posted quarterly Income from Non-Controlling Interests of -$1.0 million for Q1 2019, down 171.43% year-over-year from $1.4 million in Q1 2018, and up 41.18% quarter-over-quarter from -$1.7 million in Q4 2018.
Regeneron Pharmaceuticals (REGN) Income from Non-Controlling Interests (2017 - 2019) Analysis & Trends
Regeneron Pharmaceuticals' Income from Non-Controlling Interests history runs 3 years deep, the most recent figure standing at -$1.0 million for Q1 2019.
- In Q1 2019, Income from Non-Controlling Interests fell 171.43% year-over-year to -$1.0 million; the TTM figure through Mar 2019 stood at -$1.8 million (down 181.82% YoY), while the FY2018 annual figure was $700000.0, down 12.5% from the prior year.
- Income from Non-Controlling Interests for Q1 2019 stood at -$1.0 million, up from -$1.7 million in the prior quarter.
- The five-year high for Income from Non-Controlling Interests was $1.4 million in Q1 2018, with the low at -$1.7 million in Q4 2018.
- The 3-year median for Income from Non-Controlling Interests is $164000.0 (2017), against an average of $50000.0.
- Peak annual rise in Income from Non-Controlling Interests reached 14900.0% in 2018, while the deepest fall reached 320.78% in 2018.
- Regeneron Pharmaceuticals' Income from Non-Controlling Interests stood at $770000.0 in 2017, then sank by 320.78% to -$1.7 million in 2018, then soared by 41.18% to -$1.0 million in 2019.
- Business Quant data shows REGN's Income from Non-Controlling Interests at -$1.0 million in Q1 2019, -$1.7 million in Q4 2018, and $300000.0 in Q3 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 63.60 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -100.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2019 | -1.00 Mn |
| Dec 31, 2018 | -1.70 Mn |
| Sep 30, 2018 | 300,000.00 |
| Jun 30, 2018 | 600,000.00 |
| Mar 31, 2018 | 1.40 Mn |
| Dec 31, 2017 | 770,000.00 |
| Sep 30, 2017 | 2,000.00 |
| Jun 30, 2017 | 28,000.00 |